We Help Companies Find New Sales Opportunities
Galen has sold its UK-based pharmaceutical sales and marketing operation to its founder for £40m, and has also announced the sale of its sterile fluids solutions business to Gambro BCT of the US for £2.5m.
Galen Holdings has sold its Pharmaceutical Development and Manufacturing Services business to the company's founder and former Chairman for £20m.
Galen has announced the £10m sale of its Interactive Clinical Technologies business to its founder, who also acquired the main clinical trials operation in May.
Galen is to sell its clinical trials business to its founder for £130m, in order to focus on pharmaceuticals production.
Galen is selling Chemical Synthesis Services, a small-scale drug manufacturing business with 110 staff in Northern Ireland, to its founder for £25m.
Galen is looking to expand its pharmaceuticals business in continental Europe and the US, but its services division, which prepares medicines for clinical trials, is now regarded as non-core.
Galen is looking to spend up to £700m on acquisitions to expand its pharmaceuticals business, and is particularly interested in US companies, small biotechnology groups and companies with a European salesforce.
Galen is to acquire Warner Chilcott, the US supplier of women's health products, for £190m.
Galen is to create a further 300 jobs at its pharmaceutical sites in Craigavon and Larne over the next three years, in a £40m investment.
Galen is to acquire the product range of Bartholemew Rhodes, the Northamptonshire-based pharmaceutical company, for £20m.
Galen has announced plans for a £21m expansion of its pharmaceutical activities in Northern Ireland, which will lead to 63 new jobs at its Craigavon headquarters and 40 jobs in its SynGal division.
Galen Holdings, the pharmaceuticals concern, has announced a £17m expansion in Northern Ireland, creating 160 jobs.